Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hardy

Showing results (491-500 of 504) with videos related to

Pageof 51
Sort By:
Nature Genetics|May 1, 1994
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACsL L Green, M C Hardy, C E Maynard-Currie, et al.
MMWR. Morbidity and Mortality Weekly Report|January 4, 2019
Notes from the Field: Environmental Investigation of a Multistate Salmonellosis Outbreak Linked to Live Backyard Poultry from a Mail-Order Hatchery - Michigan, 2018Margaret C Hardy, Scott A Robertson, Jennifer Sidge, et al.
Annals of the New York Academy of Sciences|September 29, 1995
Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACsA Jakobovits, L L Green, M C Hardy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trialP Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Gynecologic Oncology|July 7, 2020
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG networkF Derquin, A Floquet, A C Hardy-Bessard, et al.
Plos Neglected Tropical Diseases|April 28, 2025
Proceedings of the second annual dengue endgame summit: A call to actionCéline S C Hardy, Lauren E Bahr, Alan L Rothman, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Pageof 51

Showing results (491-500 of 504) with videos related to

Sort By:
Pageof 51
Nature Genetics|May 1, 1994
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACsL L Green, M C Hardy, C E Maynard-Currie, et al.
MMWR. Morbidity and Mortality Weekly Report|January 4, 2019
Notes from the Field: Environmental Investigation of a Multistate Salmonellosis Outbreak Linked to Live Backyard Poultry from a Mail-Order Hatchery - Michigan, 2018Margaret C Hardy, Scott A Robertson, Jennifer Sidge, et al.
Annals of the New York Academy of Sciences|September 29, 1995
Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACsA Jakobovits, L L Green, M C Hardy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trialP Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Gynecologic Oncology|July 7, 2020
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG networkF Derquin, A Floquet, A C Hardy-Bessard, et al.
Plos Neglected Tropical Diseases|April 28, 2025
Proceedings of the second annual dengue endgame summit: A call to actionCéline S C Hardy, Lauren E Bahr, Alan L Rothman, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Pageof 51